SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bruce Rosen who wrote (781)11/18/1997 10:00:00 AM
From: Cacaito  Read Replies (1) of 7041
 
Bruce, Asencio is not a regular short, he goes after a company with lots of research behind, and he does find the way to get data out on which to base their decisions.

I do think that the risk for Zona is highly increased.

Remember when Asencio went after Solv-Ex, it is now in bankruptcy proceedings and the shares are less than $3 (when removed out of the Nasdaq, who knows how many cents is value at this moment).

Zona will have to release all their data in order to fight Asencio.

My believe was the patent (the lack of a valid one) will give trouble after marketing, but it looks like the generic troubles will not wait, it is here.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext